PARP1 and prostate carcinoma: Synergistic anti‐cancer effects in prostate cancer were reported by co‐treatment of Docetaxel and gamma‐tocotrienol on apoptosis mechanisms by upregulating the pro‐apoptotic proteins (caspases 3, 7, 8, 9, and cleaved PARP) and downregulating pro‐survival proteins (Id‐1, NF‐kB, p65, ik‐B, and EGF‐R).56